CTI BioPharma appoints Alan Burnett lead, myeloid diseases
This article was originally published in Scrip
Executive Summary
CTI BioPharma has named Dr Alan K Burnett therapeutic area lead for myeloid disease. Dr Burnett was most recently professor and head of the department of hematology in the Institute of Cancer and Genetics at Cardiff University. He will be responsible for creating and implementing the strategic development program for CTI's compounds in myeloid malignancies with a major focus on supplementing the company's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.